2-(2-fluorophenyl)-6-methyl-4H-benzo[d][1,3]oxazin-4-one | 301193-57-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 2-(2-fluorophenyl)-6-methyl-4H-benzo[d][1,3]oxazin-4-one
• 英文别名: 2-(2-Fluoro-phenyl)-6-methyl-3,1-benzoxazin-4-one；2-(2-fluorophenyl)-6-methyl-4H-3,1-benzoxazin-4-one；2-(2-fluorophenyl)-6-methyl-3,1-benzoxazin-4-one
• CAS: 301193-57-7
• 化学式: C₁₅H₁₀FNO₂
• 分子量: 255.248
• InChiKey: QRCXZUUJIIYGRU-UHFFFAOYSA-N

物化性质

• 沸点：
  377.8±31.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4H-3,1-苯并噁嗪-4-酮,6-甲基-2-苯基- 在 silver nitrate 、 N-氟代双苯磺酰胺 、 palladium dichloride 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 24.0h， 以63%的产率得到2-(2-fluorophenyl)-6-methyl-4H-benzo[d][1,3]oxazin-4-one
  参考文献：
  名称：

  硝酸盐作为关键促进剂的钯催化2-芳基苯并[d]恶嗪酮的CH键全氟化

  摘要：

  摘要 N-氟苯磺酰亚胺（NFSI）通过钯催化以中等到良好的产率实现了2-芳基苯并[ d ]恶嗪酮的单氟化。在硝酸盐的促进下，该反应提供了经济和环境友好的策略。单氟2-芳基苯并[ d ]恶嗪酮的合成与许多常见的官能团具有良好的相容性。讨论了这种单氟化的可能机理。 N-氟苯磺酰亚胺（NFSI）通过钯催化以中等到良好的产率实现了2-芳基苯并[ d ]恶嗪酮的单氟化。在硝酸盐的促进下，该反应提供了经济和环境友好的策略。单氟2-芳基苯并[ d ]恶嗪酮的合成与许多常见的官能团具有良好的相容性。讨论了这种单氟化的可能机理。

  DOI：

  10.1055/s-0037-1611700

文献信息

• Inhibitors of the tissue factor/factor VIIa-induced coagulation: synthesis and in vitro evaluation of novel specific 2-aryl substituted 4 H -3,1-benzoxazin-4-ones
  作者：Palle Jakobsen、Bo Ritsmar Pedersen、Egon Persson

  DOI：10.1016/s0968-0896(00)00129-2

  日期：2000.8

  The synthesis of a series of novel 2-aryl substituted 4H-3,1-benzoxazin-4-ones and their evaluation as specific inhibitors of the Tissue Factor (TF)/Factor VIIa (FVIIa)-induced pathway of coagulation is reported. Inhibitory activities (IC50 values) in the range 0.17 to > 40 mu M on the activation of Factor X (FX) by the TF/FVIIa complex were found for compounds having one or two electronegative substituents such as F, Cl and NO2 in the 2-aryl substituent. Different substitutions both electron-attracting and donating groups were allowed in the 5, 6, 7 and 8 positions. Several of the compounds showed a selectivity ratio towards FX and thrombin of > 50, thus being the first small molecules described as potential drugs for oral antithrombotic treatment without side effects such as bleeding which is observed especially with thrombin inhibitors. The best substituent pattern being the 2-aryl group substituted with: 2-F; 2,6-F-2; or 2-FX; 6-Cl; together with electronegative substitution in the 5, 6, 7, or 8 positions. 7-Heteroaryl substituents like thienyl and furanyl were of low activity while some 2-(2-chloro-3-pyridyl) derivatives had inhibitory activity < 10 mu M and a good selectivity. (C) 2000 Elsevier Science Ltd. All rights reserved.
• USE OF FUSED HETEROCYCLIC COMPOUNDS AS SCCE INHIBITORS FOR THE TREATMENT OF SKIN CONDITIONS OR CANCER
  申请人：Arexis AB

  公开号：EP1631295A2

  公开（公告）日：2006-03-08
• Use of heterocyclic compounds as scce inhibitors
  申请人：Linschoten Marcel

  公开号：US20060258651A1

  公开（公告）日：2006-11-16

  The present invention relates to heterocyclic inhibitors of stratum corneum chymotryptic enzyme (SCCE). More particularly, the invention relates to the use of compounds with the formula (I) or (II) for treatment of certain diseases, in particular skin diseases such as pruirtus, as well as cancer such as ovarian cancer.
• US6180625B1
  申请人：——

  公开号：US6180625B1

  公开（公告）日：2001-01-30
• US7872052B2
  申请人：——

  公开号：US7872052B2

  公开（公告）日：2011-01-18